Peter Svalander

Corporate Officer/Principal at University of Gothenburg

Consumer Services

Commercial Services

Profile

Peter Svalander is a Professor at the University of Gothenburg.
Prior to this, he worked as a Director at Avaris AB and as President at Swedish Biotechnology AB.

Peter Svalander active positions

Companies	Position	Start
University of Gothenburg	Corporate Officer/Principal	01/06/2010

All active positions of Peter Svalander

Former positions of Peter Svalander

Companies	Position	End
Swedish Biotechnology AB	President	-
Avaris AB Avaris AB Miscellaneous Commercial ServicesCommercial Services Avaris was founded in 2001 by research teams at the Karolinska Institute and Karolinska Innovations AB. The company is based on four proprietary technology platforms within cell and gene therapy. Avaris drives the research development and commercialization of new therapies in close collaboration with the founders, research teams, and strategic partners. The company is well positioned in cell and gene therapy field for chronic infections, cancer and inherited diseases. Avaris vision is to become the number one supplier of individualized cell and gene therapy treatments in northern Europe. In order to reach this goal it is exploring possibilities to acquire, or in license cell therapy technologies that complement the in house growth. Avaris is also open to partnering possibilities.	Director/Board Member	-

See the detail of Peter Svalander's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Peter Svalander's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Swedish Biotechnology AB
Avaris AB Avaris AB Miscellaneous Commercial ServicesCommercial Services Avaris was founded in 2001 by research teams at the Karolinska Institute and Karolinska Innovations AB. The company is based on four proprietary technology platforms within cell and gene therapy. Avaris drives the research development and commercialization of new therapies in close collaboration with the founders, research teams, and strategic partners. The company is well positioned in cell and gene therapy field for chronic infections, cancer and inherited diseases. Avaris vision is to become the number one supplier of individualized cell and gene therapy treatments in northern Europe. In order to reach this goal it is exploring possibilities to acquire, or in license cell therapy technologies that complement the in house growth. Avaris is also open to partnering possibilities.	Commercial Services